Creating Hope Reauthorization Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Creating Hope Reauthorization Act of 2024 is a Senate bill introduced in the 118th Congress aimed at reauthorizing provisions related to the Creating Hope Act, which typically involves incentives for developing treatments for rare pediatric diseases. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on June 18, 2024. However, the bill ultimately failed or expired without further legislative action. No official summary or full text is available to provide detailed provisions or changes proposed in this reauthorization effort.
This bill sought to continue or renew existing legislative incentives for pediatric rare disease treatments but did not advance beyond committee referral and expired in the 118th Congress.
- The bill is a Senate-originated reauthorization effort related to the Creating Hope Act.
- It was referred to the Senate Committee on Health, Education, Labor, and Pensions after initial readings.
- The bill did not progress further and is listed as failed or expired.
['Pharmaceutical and biotechnology companies engaged in developing treatments for rare pediatric diseases', 'Children and families affected by rare pediatric diseases', 'Health agencies involved in rare disease treatment oversight and support']
['Lack of available full text and official summary limits transparency and understanding of specific provisions or changes proposed', 'Failure to pass may result in discontinuation of incentives or programs supporting rare pediatric disease treatment development', 'Potential oversight and funding implications remain unclear due to missing detailed legislative text']
The bill was introduced in the Senate during the 118th Congress and referred to the relevant health committee. The Creating Hope Act has been part of prior legislative efforts to incentivize development of treatments for rare pediatric diseases. The failure or expiration of this reauthorization bill means no legislative update or continuation was enacted during this session.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Without reauthorization, incentives for pharmaceutical companies to develop rare pediatric disease treatments may diminish, potentially slowing innovation in this area.', 'Families and patients affected by rare pediatric diseases might face delays or reduced access to new therapies if development incentives lapse.', 'Health agencies may experience changes in program funding or authority related to rare disease treatment support.']
The absence of an official summary and full bill text reduces transparency and limits the ability of the public and oversight bodies to fully evaluate the bill's provisions and potential impacts. The bill's failure to advance past committee referral highlights the importance of tracking legislative progress to understand which health policy initiatives are actively supported or stalled.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.